Clinical indications for, and the future of, circulating tumor cells

Dominic H. Moon; Daniel P. Lindsay; Seungpyo Hong; Andrew Z. Wang

doi:10.1016/j.addr.2018.04.002

Clinical indications for, and the future of, circulating tumor cells

Dominic H. Moon, Daniel P. Lindsay, Seungpyo Hong, Andrew Z. Wang

Department of Pharmacy

Research output: Contribution to journal › Review article › peer-review

20 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow.

Original language	English
Pages (from-to)	143-150
Number of pages	8
Journal	Advanced Drug Delivery Reviews
Volume	125
DOIs	https://doi.org/10.1016/j.addr.2018.04.002
Publication status	Published - 2018 Feb 1

Bibliographical note

Funding Information:
A.Z.W is supported by funding from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) ( U54CA198999 , Carolina Center of Cancer Nanotechnology Excellence (CCNE) Nano Approaches to Modulate Host Cell Response for Cancer Therapy ). A.Z.W. is also supported by funding from the NIH/NCI (U54 CA151652 and R01 CA178748) and NIH/NCI (R21 CA182322).

All Science Journal Classification (ASJC) codes

Pharmaceutical Science

Access to Document

10.1016/j.addr.2018.04.002

Fingerprint Dive into the research topics of 'Clinical indications for, and the future of, circulating tumor cells'. Together they form a unique fingerprint.

Cite this

@article{6b2cef303f95461398889b66662e50d7,

title = "Clinical indications for, and the future of, circulating tumor cells",

abstract = "Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow.",

author = "Moon, {Dominic H.} and Lindsay, {Daniel P.} and Seungpyo Hong and Wang, {Andrew Z.}",

note = "Funding Information: A.Z.W is supported by funding from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) ( U54CA198999 , Carolina Center of Cancer Nanotechnology Excellence (CCNE) Nano Approaches to Modulate Host Cell Response for Cancer Therapy ). A.Z.W. is also supported by funding from the NIH/NCI (U54 CA151652 and R01 CA178748) and NIH/NCI (R21 CA182322).",

year = "2018",

month = feb,

day = "1",

doi = "10.1016/j.addr.2018.04.002",

language = "English",

volume = "125",

pages = "143--150",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Clinical indications for, and the future of, circulating tumor cells

AU - Moon, Dominic H.

AU - Lindsay, Daniel P.

AU - Hong, Seungpyo

AU - Wang, Andrew Z.

N1 - Funding Information: A.Z.W is supported by funding from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) ( U54CA198999 , Carolina Center of Cancer Nanotechnology Excellence (CCNE) Nano Approaches to Modulate Host Cell Response for Cancer Therapy ). A.Z.W. is also supported by funding from the NIH/NCI (U54 CA151652 and R01 CA178748) and NIH/NCI (R21 CA182322).

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow.

AB - Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making. These include using CTCs as a screening tool for diagnosis, liquid biopsy for molecular profiling, predictive biomarker to specific therapies, and monitoring tool to assess response and guide changes to treatment. CTCs have unique advantages vs circulating tumor DNA in this endeavor. Indications for CTCs in daily practice will expand as isolation techniques improve and clinical studies validating their utility continue to grow.

UR - http://www.scopus.com/inward/record.url?scp=85045129013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045129013&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2018.04.002

DO - 10.1016/j.addr.2018.04.002

M3 - Review article

C2 - 29626548

AN - SCOPUS:85045129013

VL - 125

SP - 143

EP - 150

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -